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Objectives The goal of this study was to explore the effects of angiogenic gene therapy.
Background Preclinical studies with intracoronary administration of Ad5FGF-4 (alferminogene tadenovec, Generx, Berlex Bio-
sciences, Richmond, California) suggested it could induce angiogenesis and provide a new clinical approach to
the treatment of chronic angina pectoris. Two preliminary clinical trials provided evidence that it could im-
prove exercise treadmill test (ETT) time and myocardial perfusion. The AGENT (Angiogenic GENe Therapy)-3
and -4 trials of a low and high dose of Ad5FGF-4 for chronic angina were initiated in the U.S. and other
countries and enrolled 532 patients in a randomized, double-blind, placebo-controlled fashion. Both studies
were halted when an interim analysis of the AGENT-3 trial indicated that the primary end point change from
baseline in total ETT time at 12 weeks would not reach significance.
Methods We performed a pooled data analysis from the 2 nearly identical trials to investigate possible treatment effects
on primary and secondary end points in prespecified subgroups.
Results The effect of placebo was large and not different than active treatment in men, but the placebo effect in women
was negligible and the treatment effect was significantly greater than placebo. We found a significant, gender-
specific beneficial effect of Ad5FGF-4 on total ETT time, time to 1 mm ST-segment depression, time to angina,
and Canadian Cardiovascular Society class in women. This is the first clinical report of a gender difference in
response to cardiac angiogenic therapy.
Conclusions The potential importance of the observed gender-specific angiogenic response on the clinical treatment of re-
fractory angina is substantial and deserves further investigation. (Efficacy and Safety of Intracoronary Ad5FGF-4
in Patients With Stable Angina; http://www.clinicaltrials.gov/ct/show/NCT00346437; NCT00346437) (Safety and
Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina [AGENT-4]; http://www.clinicaltrials.gov/ct/show/
NCT00185263; NCT00185263) (AWARE; http://www.clinicaltrials.gov/ct/show/NCT00438867; NCT00438867)
(J Am Coll Cardiol 2007;50:1038–46) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.010n
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ingina pectoris is a disabling manifestation of coronary
rtery disease (CAD). In the U.S., 8.9 million people live
ith chronic angina, and an additional 400,000 people are
ewly diagnosed each year (1). There are 2 major mecha-
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alifornia; and the #University of California, San Diego, California. Supported, in
art, by Schering AG, Berlin, Germany; Berlex Laboratories, Inc., Montville, New
ersey; and Cardium Therapeutics, Inc., San Diego, California. Dr. Moreadith and
r. Andrasfay are employees of Cardium Therapeutics, Inc. (CTI). Dr. Engler is a
aid consultant to CTI. Dr. Watkins has received limited consulting fees from CTI.t
Manuscript received January 9, 2007; revised manuscript received June 7, 2007,
ccepted June 8, 2007.istic approaches to the treatment of chronic angina. First,
urrently approved drug therapy includes beta-blockers,
alcium-channel blockers, long-acting nitrates, and, most
ecently, ranolazine. Drug therapy alters the supply/demand
elationship between the coronary arterial tree blood flow
nd cardiac muscle oxygen requirements. Second, revascu-
arization by angioplasty, stent, or bypass surgery either
eopens or bypasses blockages in the epicardial vessels.
owever, many patients continue to have recurrent angina
ith drug therapy and are not suitable for revascularization
rocedures (1). New mechanistic approaches are needed to
mprove blood flow to the myocardium (2).
In contrast to the mechanisms involved in approved
herapeutic methods, the heart’s natural responses to isch-
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September 11, 2007:1038–46 Ad5FGF-4 in Chronic Anginamia include arteriogenesis and angiogenesis leading to the
evelopment of coronary collaterals. However, in patients
ith persistent angina, collateral formation is inadequate
nd/or the process stops before stress-induced ischemia is
elieved (2). Enhancing angiogenesis and collateral forma-
ion represents a new mechanistic approach for which there
re no approved products (2,3). Pioneering work by Dr.
effery Isner and colleagues showed the feasibility of aug-
enting angiogenesis (4–6). A series of promising phase 1
rials have led to a number of phase 2 randomized placebo-
ontrolled trials with angiogenic proteins (7–10) and growth
actor gene therapy (11–15).
The preclinical development of the angiogenic therapy
roduct Ad5FGF-4 (replication deficient, E1A/E1B-
eleted, human adenovirus serotype 5 with human FGF-4
ene insert: alferminogene tadenovec, Generx, Berlex Bio-
ciences, Richmond, California) began with a pig model of
oronary ameroid occlusion. In this model of chronic,
tress-induced ischemia, intracoronary administration of
first-generation serotype 5 adenovector with either the
GF-5 gene (16) or FGF-4 gene (17) inserted increased
ngiogenesis evidenced by histology and relieved the
tress-induced ischemia evidenced by increased left ven-
ricular blood flow and function. Furthermore, there was
emarkably high first pass uptake in the heart. High first
ass uptake by the heart and preliminary evidence of
fficacy were confirmed in an ascending-dose clinical trial
n patients with refractory angina (AGENT [Angiogenic
ENe Therapy]-1) (11), and a subsequent myocardial
tress perfusion study (AGENT-2) confirmed increased
ow (12). Based on these results, the phase 2b/3
GENT-3 trial was initiated by Berlex in the U.S., and
GENT-4 was initiated by Schering AG in Europe,
atin America, and Canada (Berlex Canada). These trials
nrolled a total of 532 patients under nearly identical
rotocols before enrollment in both trials was discontin-
ed as described in the following text.
A preliminary cluster analysis of the AGENT-3 trial
uggested a positive effect in some subgroups. Accordingly,
e have performed an analysis of pooled original data from
he AGENT-3 and -4 trials to investigate whether gender
nd older patients with severe angina subgroups would show
ossible treatment effects, and to ascertain if significant new
ypotheses could be generated given the positive results of
he AGENT-2 trial. We report here a positive response in
linical symptoms overall and a markedly positive effect in
omen, suggesting a gender-specific effect.
ethods
GENT-3 and -4 protocols. The AGENT-3 trial was
nitiated in October 2001 and the AGENT-4 trial in March
002. Enrollment was stopped for both trials in January
004, when a planned interim analysis of the AGENT-3
rial revealed the study was unlikely to yield a statistically
ignificant result on the primary efficacy end point of change irom baseline in exercise tread-
ill time duration at 12 weeks.
oth trials were designed as
arallel group, double-blind,
lacebo-controlled, randomized
tudies using 2 active dose groups;
low dose of Ad5FGF-4, 1 109
iral particles (vp), a high dose of
 1010 vp, and placebo in a
:1:1 randomization ratio with
replanned interim analyses.
rotocols were approved by each
nstitution’s institutional review
oard for human subjects. Pa-
ients providing informed con-
ent included patients 30 to 75
ears of age with a history of
ecurrent stable angina (Canadian
ardiovascular Society [CCS]
lass II to IV) who remained symptomatic despite antian-
inal medication and who did not require immediate per-
utaneous coronary intervention (PCI) or coronary artery
ypass graft (CABG) surgery (AGENT-3) or were techni-
ally unsuitable for PCI or CABG (AGENT-4); the latter
riteria was the only difference between the 2 studies.
atients had a left ventricular ejection fraction of 30%
easured within 12 months of enrollment. Patients had 1-,
-, or 3-vessel CAD, but patients with 3-vessel disease had
o have at least 1 proximal major vessel or graft with 70%
tenosis (to provide a conduit to collateral vessels).
To be randomized for treatment, patients had to be able
o exercise for at least 3 min but no more than 10 min, and
top for moderately severe angina (grade 3 or 4 on a 1 to 4
cale) on the first qualifying baseline exercise tolerance test
ETT) using the modified Balke-Ware exercise protocol.
atients had to demonstrate 1 mm ST-segment depres-
ion (horizontal or down sloping) from baseline in the
ualifying ETT. The variability in exercise duration (time to
rade 3/4 angina or angina equivalent) had to be within 20%
n 2 consecutive qualifying tests. The ETTs were per-
ormed in the morning with all antianginal medication
ithheld. The individual patient’s antianginal medication
ad to be stable for 4 weeks before enrollment.
Exclusion criteria included patients with unstable angina,
lectrocardiograms unable to show myocardial ischemia
e.g., left bundle branch block, Wolff-Parkinson-White
yndrome, atrial fibrillation), illness that might interfere
ith the patients’ ability to perform the ETT, untreated
ife-threatening ventricular arrhythmias, left main coronary
rtery stenosis 70% unless bypassed by a patent graft,
ABG surgery in the past 6 months unless all vessels were
00% occluded, myocardial infarction in the last 8 weeks,
ongestive heart failure (New York Heart Association
NYHA] functional class IV) despite treatment, PCI in the
revious 6 months, prior transmyocardial laser revascular-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CCS  Canadian
Cardiovascular Society
ETT  exercise tolerance
test
FGF  fibroblast growth
factor
NYHA  New York Heart
Association
PCI  percutaneous
coronary intervention
VEGF  vascular
endothelial growth factorzation, enhanced external counterpulsation within 12
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Ad5FGF-4 in Chronic Angina September 11, 2007:1038–46eeks, moderate-to-severe nonproliferative or proliferative
etinopathy from any cause (ETDRS [Early Treatment
iabetic Retinopathy Study] score 35), clinically signifi-
ant macular edema or previous photocoagulation therapy,
reatinine clearance 45 ml/min using the Cockcroft and
ault formula, immunosuppression therapy, and women of
hild-bearing potential (see NCT00346347 for further de-
ails). Patients were screened for cancer along the guidelines
f the American Cancer Society. Patients were followed
ith clinic visits at weeks 2, 4, 8, and 12, and at months 6,
2, 18, and 24 with yearly telephone contact to continue
hrough November 2008. Every effort was made to keep
ardiovascular medication constant unless required by
hanges in clinical condition.
Treatment group allocation was randomized centrally and
linded to everyone except the data safety monitoring board
tatistician. After screening and randomization, using rou-
ine cardiac catheterization procedures, Ad5FGF-4 was
elivered by intracoronary infusion over 90 s per injection
ollowed by a 5-ml 90-s flush, with the dose divided among
ll major coronary arteries (right coronary artery, circumflex,
eft anterior descending coronary, and bypass grafts) target-
ng 60% of the total dose to the left coronary system and
0% to the right coronary system. A standard subselective
atheter of the investigators’ choice was used from among 4
atheters that had been shown to be biocompatible with
d5FGF-4.
tatistical analysis. The primary end point in the
GENT-3 and -4 trials was change from baseline in total
TT time at 12 weeks, and at secondary time points of 4
eeks and 6 months. Prespecified secondary end points in
oth studies included time to 1 mm ST-segment depres-
ion, time to onset of angina, change in CCS class,
ercentage of patients with 30% increase in ETT, coro-
ary events or death at 1 year, change in angina incidence
nd nitroglycerin use by patient diary, and change in quality
f life. Subgroup analyses by gender, age, and angina
everity were also prespecified in the AGENT-3 and -4
rials.
Based on the results of a cluster analysis of the
GENT-3 trial, we performed a pooled data analysis to
dentify whether there was an overall effect, and whether the
ubgroups of gender and older patients with more severe
ngina led to plausible hypotheses worthy of further clinical
esting. The AGENT-3 and -4 trial databases were concat-
nated since the case report forms were identical, resulting
n a pooled database. For safety data, all observations were
ncluded. For primary and secondary end points, a valid
atient population was used. Thus, we censored at least 1
nvalid ETT result in 15 patients (2 women) in whom the
TT protocol was not conducted according to the modified
alke-Ware protocol making the ETTs not comparable.
e also censored ETT data from 22 patients (1 woman)
btained after an interim revascularization, angioplasty, or
ABG, or who did not have an ETT at week 12. Only svailable data were used; we did not carry forward last
bservations when data were missing.
A 2-way analysis of variance (ANOVA) was used to test
or gender subgroup interaction with primary and secondary
nd points. The Wilcoxon rank sum test was used for
ifferences in primary and secondary end points between
atient groups. We report here only prespecified subgroup
nalyses and primary and secondary end points from the
tatistical analysis plan for the pooled analysis. Since this
ooled analysis was hypothesis-generating, we report both
ncorrected p values and note where the Bonferroni correc-
ion for the 3 subgroups (men, women, and older patients
ith more severe angina) remains significant (p  0.0167).
esults
he AGENT-3 trial enrolled 139 placebo, 137 low-dose,
nd 140 high-dose patients, and the AGENT-4 trial
nrolled 38 placebo, 43 low-dose, and 35 high-dose patients
or a total of 532 patients in the 2 studies. There were 489
atients with evaluable ETT data at 12 weeks including 163
lacebo, 163 low-dose, and 163 high-dose patients available
or analysis. Separate analysis of the AGENT-3 and -4
rials failed to show any differences between placebo and
reatment for any primary or secondary end points, with the
xception of older patients with more severe angina and
CS class in the AGENT-3 trial, differences largely due to
he female cohort. The results of the 2 trials were quite
imilar; therefore, we report here only the pooled analysis
esults.
rimary and secondary end points. In the valid case
opulation (and the intent-to-treat population), using the
ooled data from the 2 studies, there was no significant
ifference between the active groups and the placebo for the
rimary end point, change from baseline exercise time at 12
eeks (Fig. 1). There was a large and significant placebo
ffect compared with baseline, which persisted over 6
onths. There were no differences between either dose
roup and placebo for any of the secondary end points
xcept for CCS class. Subgroup analysis did show a signif-
cant effect on the primary end point in older patients with
ore severe angina. As discussed in the following text, these
ifferences were biased by a large effect in women, and no
ffect in men.
linical effects. The distribution of changes from baseline
or CCS class for all patients was significantly improved
ver placebo only for the high-dose group at week 12,
onth 6, and month 12 (p  0.05). The latter effect was
riven by the female population; in the male only subgroup,
here was no significant change in CCS class. The changes
n Seattle Angina Questionnaire, Medical Outcomes Study
hort Form 36, angina frequency, or nitroglycerin use were
ot significant.
ubgroup of older patients with more severe angina. Sub-
roup analysis in all patients over age 55 years with more
evere angina at baseline (CCS III or IV) also showed
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September 11, 2007:1038–46 Ad5FGF-4 in Chronic Anginaignificant differences or trends in primary and secondary
nd points. Possible trends were not present in the male
nly population. None of these end points remains signifi-
ant after Bonferroni correction.
ubgroups by gender. The baseline exercise times for men
ere not different across treatment groups, but for women
aseline ETT time for the high dose was less than for the
ow dose (Table 1). Baseline CCS class was also similar
cross treatment groups for both gender subgroups, with
ean values for women of 2.8 for placebo, 2.6 for low dose,
nd 3.0 for high dose.
Prespecified subgroup analysis by gender at 12 weeks of
ollow-up revealed a significant effect in women in the
rimary end point, total ETT time, for both dose groups
Fig. 2, Table 1) (n  72), but no effect in men (n  417).
he gender treatment interaction by 2-way ANOVA for
otal ETT time was significant for the high-dose group at
2 weeks and 6 months. The difference between men and
omen was due to a negligible placebo effect in women
ompared with a large placebo effect in men, as the
mprovement in total ETT time over baseline in both active
ose groups was similar in men and women. The gender-
Figure 1 Change in ETT Time for All Patients
Change from baseline in total exercise time for all valid case patients (men
and women) at 4 weeks, 12 weeks, and 6 months. Data are mean and stan-
dard error. ETT  exercise treadmill test; vp  viral particles.
Total Exercise Time Results (Seconds) in Fema
Table 1 Total Exercise Time Results (Secon
Placebo
Study Visit n Mean (S
Baseline 31 345 (13
Week 4 change from baseline 31 22 (73
Week 12 change from baseline 30 4 (97
Month 6 change from baseline 28 6 (14*p  0.05 versus low dose; †p  0.05 versus placebo; ‡p  0.01 versus pla
vp  viral particles.pecific effect was also significant in women, or nearly so, for
oth active dose groups in the secondary end points of time
o 1 mm ST-segment depression, time to angina, and CCS
lass (Figs. 3 to 5) at both 12 weeks and 6 months. The
hanges observed from baseline in the end points of total
TT time, time to 1 mm ST-segment depression, and CCS
lass and their p values suggested a dose-response effect.
he primary end point (Table 1) and secondary end points
Figs. 3 to 5) remained significant after Bonferroni correc-
ion mostly for the high-dose group. There were no trends
or efficacy in any of these end points in men. The durability
f the effect was supported by a significant improvement in
CS class at 12 months in women (Fig. 5), but not in men
data not shown).
ffect at 6 and 12 months in women. Positive effects were
een only in the female subgroup and not in the population
s a whole. In general, the positive effects on ETT duration,
ime to 1 mm ST-segment change, and time to angina in
he female population were either significant or at least
howed a nearly significant trend at 6 months (Figs. 3 and
). The durability of the effect is confirmed by sustained
mprovement in CCS class at 12 months (Fig. 5).
Figure 2 Change in ETT Time at Week 12 by Gender
Change from baseline in total exercise time at week 12 by gender. Data are
mean and standard error. *p  0.05, †p  0.01, ‡p  0.0167 (Bonferroni
correction for subgroup analysis). Abbreviations as in Figure 1.
tients
n Female Patients
Ad5FGF-4
1  109 vp 1  1010 vp
n Mean (SD) n Mean (SD)
22 372 (97) 20 300 (74)*
22 20 (116) 19 1 (69)
22 60 (99)† 20 69 (83)‡§
22 75 (136)† 18 83 (113)‡§le Pa
ds) i
D)
0)
)
)
9)cebo; §p  0.0167 (Bonferroni correction).
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Ad5FGF-4 in Chronic Angina September 11, 2007:1038–46ardiovascular safety. Follow-up data for death and se-
ere adverse cardiovascular events (myocardial infarction
nd unplanned hospitalization or revascularization due to
yocardial ischemia) occurring during the first 12 months
fter treatment were adjudicated by the clinical events
ommittees for each trial. The incidence of the composite
nd point was not different across the groups: 22% placebo,
6% low dose, 19% high dose. In the gender subgroups, the
ncidences were 30% placebo, 9% low dose, and 19% high
ose in women and 20%, 17%, and 19%, respectively, in
en.
Figure 3 Change in Time to Onset of 1 mm
ST-Segment Change in Female Patients
Change from baseline in time to onset of 1 mm ST-segment change in female
patients. Data are mean and standard error. vp  viral particles. *p  0.05,
‡p  0.0167 (Bonferroni correction for subgroup analysis).
Figure 4 Change in Time to Onset
of Angina in Female Patients
Change from baseline in time to onset of angina in female patients. Data are
mean and standard error. vp  viral particles. †p  0.01, ‡p  0.0167
(Bonferroni correction for subgroup analysis).Cdverse events. No significant safety concerns for
d5FGF-4 were identified by the data and safety monitor-
ng boards who reviewed the safety data for the AGENT-3
nd -4 trials at the interim analyses. For this analysis,
dverse event data were available for a minimum of 23
onths and a maximum of 50 months of follow-up. The
ncidence of cardiovascular adverse events (death, myocar-
ial infarction, worsening angina, unstable angina, chest
ain, cardiac arrest, congestive heart failure, or cerebrovas-
ular accident) (some patients had more than one)/total
umber of patients, and mean number of adverse events/
atient for placebo, low- and high-dose in men were 91/145
0.63), 81/158 (0.51), and 94/154 (0.61). The respective
umbers in women were 31/33 (0.94), 7/22 (0.32), and 9/21
0.43). Transient fever occurred in 3.4% of placebo and
.6% of active treatment patients (p  0.038). This is an
nfrequent but expected side effect of adenoviral gene
herapy. The majority of fevers that occurred within the first
ew days after study product administration resolved with no
reatment or with antipyretic medication. Hemodynamics
uring and after product administration were stable. There
as no evidence for pathological angiogenesis or ophthal-
ologic changes (neovascularization or progression of the
TDRS score). The incidence of angina/worsening angina
as significantly lower (p  0.04) in active treatment
atients (17.7%) versus placebo (25.4%). There were no
ifferences in serious adverse events or other adverse events
etween the 3 groups. A Kaplan-Meier analysis of the
ncidence of cancer showed no significant difference be-
ween treatment and placebo. Other serious adverse events
hat have been observed during follow-up in single patients
n the trials were pericarditis and torsades de pointes.
Figure 5 CCS Class Improvement in Female Patients
Mean improvement over baseline in Canadian Cardiovascular Society (CCS)
class (I to IV scale) in female patients. Data are mean and standard error.
vp  viral particles. *p  0.05, †p  0.01, ‡p  0.0167 (Bonferroni correc-
tion for subgroup analysis).ollection of long-term follow-up data to assess the risk of
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September 11, 2007:1038–46 Ad5FGF-4 in Chronic Anginaelayed adverse events after intracoronary delivery of
d5FGF-4 continues for the AGENT-3 and -4 trials until
ovember 2008.
emographics. There were no significant differences at
aseline between placebo and treatment groups in age, CCS
lass, risk factors, or baseline medications. Baseline demo-
raphics between men and women were not different, but
omen had more severe angina (CCS class III and IV) than
en (Table 2), and were more likely to be on beta-blockers,
alcium-channel antagonists, long-acting nitrates, and triple
herapy (Table 3) (all p  0.05). These differences suggest
hat the women had more significant symptoms of CAD,
nd were being treated with more medications.
iscussion
afety. The AGENT trials represent the largest number of
atients treated with angiogenic gene therapy. In the
GENT-3 and -4 trials combined, 355 patients received
ctive treatment. The fever observed in 7.6% of active
reatment patients was expected and has been seen in many
denovirus vector gene transfection trials. In our pooled
nalysis, the incidence of angina/worsening angina was
tatistically less (p  0.04) in patients treated with
d5FGF-4 (17.7%) compared with that in patients who
eceived placebo (25.4%). No other adverse events were
ignificantly associated with intracoronary administration of
d5FGF-4 including cancer and undesirable angiogenesis.
here were no hemodynamic, chemical, or hematologic
hanges. Adenovirus does adhere to platelets and has been
ccasionally seen to lower platelet count, an effect we did
ot observe (18). The safety findings in the AGENT-3 and
4 trials confirm results from the AGENT-1 and -2 trials
11,12).
aseline Demographics
Table 2 Baseline Demographics
Female Patients
(n  76)
Male Patients
(n  456)
Age, mean (min, max) 63 (44, 75) 62 (41, 75)
CCS angina class*
II 30 (40%) 214 (47%)
III 33 (43%) 213 (47%)
IV 13 (17%) 29 (6%)
Heart failure NYHA functional class†
None 51 (67%) 237 (52%)
I 7 (9%) 80 (18%)
II 15 (20%) 92 (20%)
III 3 (4%) 47 (10%)
Diabetes 34 (45%) 177 (39%)
Hypertension 60 (79%) 358 (79%)
Hyperlipidemia 74 (97%) 444 (97%)
Myocardial infarction 43 (57%) 300 (66%)
PCI 53 (70%) 277 (61%)
CABG surgery 58 (76%) 377 (83%)
p  0.01 male versus female patients; †p  0.05 male versus female patients.
CABG  coronary artery bypass grafting; CCS  Canadian Cardiovascular Society; max m
aximum; min  minimum; NYHA  New York Heart Association; PCI  percutaneous coronary
ntervention.fficacy. In the valid case population (men and women) in
he pooled database for the AGENT-3 and -4 trials, the
hange from baseline in the primary end point and most of
he secondary end points showed no difference between
lacebo or either dose group. In fact, the only finding of
tatistical significance was improvement in CCS class, an
verall finding attributable mostly to the female cohort.
Previous trials of intracoronary or intravenous protein
herapy for refractory angina have not found a significant
mprovement in ETT time compared with placebo. In
IRST (FGF [fibroblast growth factor] Initiating Revascu-
arization Trial), which investigated intracoronary FGF2
rotein, both the placebo and active treatment groups
chieved an increase in ETT time in the range of 45 to 75 s
7). This remarkably large placebo effect appears to be
ommon and sustained in angiogenesis trials (19). In the
IVA (VEGF [vascular endothelial growth factor] in Isch-
mia for Vascular Angiogenesis) trial, which investigated 1
ntracoronary infusion followed by 3 intravenous infusions
f VEGF165, the improvement in ETT time in placebo
nd active was in the range of 18 to 48 s (8). Both of these
rials used the modified Bruce protocol for ETT, a more
igorous protocol at longer exercise times than the Balke-
are we employed in the AGENT trials; thus, physiolog-
cally equivalent changes would be expected to be repre-
ented by smaller ETT time changes in FIRST and VIVA
han in the AGENT trials.
The largest other trial of gene therapy for angiogenesis
sed AdVEGF121 with epicardial injection at mini-
horacotomy (REVASC [Randomized Evaluation of
EGF for Angiogenesis]). The comparison group did not
ndergo surgery but continued medical therapy. There were
ome interesting positive results or trends for improvement
n ETT time. Treated patients improved about 55 s at 26
eeks (14). Treated female patients in the AGENT-3 and
4 trial analysis, using the lower-intensity level ETT pro-
ocol, improved between 60 and 83 s, only slightly greater
han in the FIRST, VIVA, and REVASC trials.
ender-specific effect. The finding of significant treat-
ent differences in women compared with men was sur-
rising, especially since it appears to be largely due to
ifferences in placebo effect. The consistency in improve-
aseline Angina Medication Usage
Table 3 Baseline Angina Medication Usage
Female Patients
(n  76)
Male Patients
(n  456)
Beta-blockers* 74 (97%) 401 (88%)
Calcium-channel blockers* 40 (53%) 182 (40%)
Long-acting nitrates* 66 (87%) 342 (75%)
Monotherapy 8 (11%) 92 (20%)
Double therapy 30 (39%) 228 (50%)
Triple therapy or more* 38 (50%) 129 (28%)
p 0.05 male versus female patients. Classification of patients to monotherapy and double and
riple therapy groups does not total 100% in the male subset because 7 patients were not on any
hronic antianginal medication.ent for the primary end point, total ETT time, and the
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T-segment depression, and CCS class provide evidence of
real treatment effect on the underlying disease in women.
o trends for any differences were seen in the primary or
ny secondary end points in men. Total ETT time has been
he traditional end point for most antiangina intervention
rials (drugs or devices) as an objective indicator of clinical
xercise activity improvement. In women, the concordance
f improvement in CCS class confirms improvement in
aily life activities. However, the questionnaires for lifestyle
hanges did not reach significance. The significant improve-
ent in time to 1 mm ST-segment depression, as an
bjective measure of the time to onset of myocardial
schemia, further suggests a fundamental alteration in the
upply/demand relationship for myocardial blood flow after
d5FGF-4 in women.
We are aware of no prior reports of gender differences in
ngiogenesis trials. The number of women patients/total
atients enrolled and percentage of women in the 3 largest
rials were: FIRST: 54/337, 16% (5); VIVA: 21/178, 12%
6); and REVASC: 5/67, 8% (16). In the dataset for the
GENT-3 and -4 trials, the numbers were 76/532, 14%. If
he treatment arm in any of the other 3 large trials had a
ender-specific effect, the male population might com-
letely dominate any overall population observations. Fur-
hermore, the power to detect a female gender-specific
ubgroup effect would be minimal due to the low number of
omen. The AGENT trial pooled analysis would have the
reatest power to detect gender-specific effects as substan-
ially more female patients were enrolled.
The reasons for a significant treatment difference in
omen and men are unknown, but could involve hormonal
r genetic differences between the genders. There are a large
umber of sexually dimorphic genes having tissue-specific
xpression and regulation differences (20). Sexual dimor-
hism of expression in various organs ranged from a few
undred to thousands of genes with little overlap between
issues in which gene families were dimorphic. Gender-
pecific differences in atherosclerotic lesions and lipid me-
abolism in animal models are well recognized and could be
he result of differential gene expression. Gender-specific
ifferences in vascular function have also been observed.
hus, the well-recognized phenomenon of sexually dimor-
hic gene expression and differences in vascular biology
ould affect the response to angiogenic agents or the
hysiologic effects of collateral development by angiogenic
ene therapy.
The reasons for the highly significant difference in pla-
ebo effect between men and women are unknown. We
ould find no gender-specific data in the literature on
lacebo effect in CAD. There are, however, plausible
easons for the observed difference in placebo effect. One of
he mechanisms of placebo response in high technology
nterventions is the psychological effect to inspire increased
xercise training. Exercise training can improve ETT per-
ormance by both increasing peripheral efficiency (skeletal auscle/vascular training) and stimulating collateral growth.
n the AGENT trials, women tended to have more clinical
ymptoms (CCS class) and had significantly more medica-
ion usage, thus peripheral exercise training might have been
ymptomatically limited or limited by medications. This
ffect would also reduce another critical factor for collateral
rowth stimulation, namely exercise-induced increases in
lood flow. Collateral growth is importantly stimulated by
igh shear flow through microvascular channels, which is
oth pressure- and downstream-resistance–dependent, and
s increased by exercise (2). Furthermore, women are more
ikely to have microvascular dysfunction. The women in the
GENT trials could have had more intrinsic microvascular
ysfunction, which reduced the placebo-induced exercise
raining effect (more limited by more symptoms) and the
ollateral growth effect (less shear dependent stimulation of
ollateral growth).
The results of the ACIP (Asymptomatic Cardiac Ischemia
ilot) study may be relevant to our results (21,22). The
CIP study found that women presenting for treatment
ith CAD tended to have more risk factors for CAD, a
igher incidence of diabetes and hypertension, less severe
AD by angiography, shorter ETT time, but similar
umbers and duration of ambulatory electrocardiogram
bnormalities (ischemia). The demographics in the lower-
owered AGENT trials trend in a similar direction. In the
CIP study results, women and men had equivalent ische-
ic burden during daily life on ambulatory monitoring, but
omen had more risk factors and less severe angiographic
isease. One likely possibility to explain this paradox is that
omen had a greater component of microvascular disease
ot diagnosed by angiography. The observation that women
ave somewhat different symptoms and outcomes than men
nd that women less frequently receive invasive treatment
as been discussed extensively in the medical and lay
iterature (23,24). One popular hypothesis is that women
re smaller than men and have smaller hearts, thus have
ntrinsically smaller coronary arteries. The published angio-
raphic data in the ACIP study (finding relatively less
ngiographic disease associated with relatively more severe
linical disease in women compared with men) would argue
nstead that women have more microvascular disease. In
003 the American College of Cardiology reported that
early 7 million angiograms were performed, with normal
r50% stenosis being reported in 20% of men and 60% of
omen (25). Furthermore, in the WISE (Women and
schemia Syndrome Evaluation) study, 50% of women
eferred for angiograms for myocardial ischemia did not
ave significant flow-limiting lesions (26). Thus, there is
ound evidence that women have a significantly larger
omponent of microvascular disease than men contributing
o CAD symptoms.
The angiogenic response is a microvascular phenomenon,
nd arteriogenesis leading to collaterals, which occurs in the
oronary tree at the intermediate level between large vessels
nd the microcirculation, is dependent to some extent on
a
n
w
v
I
p
t
T
w
a
t
S
p
e
u
o
a
b
n
t
w
g
s
i
g
t
C
W
i
a
s
T
d
q
i
p
a
a
s
a
T
a
w
t
t
p
c
s
p
a
w
t
i
h
T
r
d
t
A
T
I
R
C
D
R
1
1
1
1
1
1
1045JACC Vol. 50, No. 11, 2007 Henry et al.
September 11, 2007:1038–46 Ad5FGF-4 in Chronic Anginangiogenesis to develop new channels that can enlarge. The
ormal human arterial tree consists of end capillary loops
ith no native collaterals, so the formation of collateral
essels is a process that must start at the microvascular level.
f women do have different microvascular physiology and
athophysiology as the literature suggests, one might expect
hem to have a different response to angiogenic stimuli.
hus, the hypothesis of more microvascular disease in
omen could explain both the lower placebo effect and an
ngiogenic effect of Ad5FGF-4 on the clinical manifesta-
ions of microvascular disease.
tudy limitations. Meta-analysis is a technique that can
otentially increase the power to detect an effect, but usually
ncounters the problems of nonidentical protocols, and
sing only statistical summary data. A pooled analysis
vercomes some of these limitations by using original data
nd, in our case, identical protocols. The only difference
etween the 2 trials was the wording of 1 entry criteria, as
oted in the preceding text, a difference not likely to effect
he hypotheses being generated. Subgroup analyses, even
hen prespecified as in this case, can only be hypothesis-
enerating. The positive results in women were statistically
ignificant after correction for subgroup comparisons mostly
n the high-dose group. Thus, our conclusion regarding a
ender-specific effect must be confirmed in subsequent
rials.
onclusions
e conclude that neither a treatment effect on the change
n ETT duration nor any other objective or subjective
ssessment of refractory angina was detectable in the male
ubgroup in the AGENT-3 and -4 trials pooled analysis.
his is in contrast to the findings in the AGENT-2 trial
emonstrating improvements in myocardial perfusion by
uantitative single-photon emission computed tomography
maging (not measured in the AGENT-3 or -4 trials) in a
opulation of predominately male patients (12). There was
remarkable difference in placebo response between men
nd women for reasons that are unclear. We found gender-
pecific female subgroup effects of Ad5FGF-4 treatment on
number of measures of the clinical manifestation of CAD.
he hypothesis of a decreased placebo response in women
nd an increased angiogenic response to Ad5FGF-4 in
omen are not mutually exclusive and may both contribute
o the current findings. These data support the hypothesis
hat there are gender different effects of angiogenic therapy,
ossibly based on differences in severity and/or location of
oronary arterial dysfunction, and/or differences in gender-
pecific gene expression.
Treatment of women with angina presents a challenging
roblem considering the underutilization of invasive therapy
nd the nearly double standardized mortality ratios in
omen compared with men (27). Management of angina in
hese patients represents an unmet clinical need that is
ncreasingly becoming one of the most pressing issues inealthcare, particularly among the aging population (28).
he potential importance of a gender-specific angiogenic
esponse on the clinical treatment of CAD is substantial and
eserves further investigation in adequately powered clinical
rials.
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APPENDIX
or a list of the clinical investigators and institutions who enrolled
atients in the AGENT-3 and -4 trials, please see the online version of this
rticle.
